Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.36 |
| ▸ | MEN1 | O00255 | 12/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | APEX1 | P27695 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300034 | 0.67 | MAPT (0.38) | MAPTMEN1KMT2AHSD17B10L3MBTL1 | |
| SCHEMBL9019949 | 0.65 | NPC1 (0.45) | LMNARAB9AALOX12 | |
| SCHEMBL10989715 | 0.65 | ALDH1A1 (0.35) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13298041 | 0.63 | PLAT (0.34) | MAPTMEN1KMT2AHSD17B10POLB | |
| SCHEMBL12048511 | 0.63 | MAPT (0.39) | MAPTMEN1KMT2AHSD17B10L3MBTL1 | |
| SCHEMBL11322094 | 0.63 | MEN1 (0.39) | MAPTMEN1KMT2AHSD17B10POLB | |
| SCHEMBL3982688 | 0.61 | MAPT (0.43) | MAPTMEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL12953043 | 0.60 | PLAT (0.33) | — | |
| SCHEMBL14397970 | 0.59 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL28836095 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287077-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2024-08-29 | — | — | US | disclosed |
| US-20220204511-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2022-06-30 | — | — | US | disclosed |
| US-20210009595-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2021-01-14 | — | — | US | disclosed |
| US-10570143-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2020-02-25 | — | — | US | disclosed |
| US-20190322669-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2019-10-24 | — | — | US | disclosed |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-07 | — | — | US | disclosed |
| EP-2920181-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIV HEALTH NETWORK (CA) | 2019-01-09 | — | — | EP | disclosed |
| US-10167289-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2019-01-01 | — | — | US | disclosed |
| US-10106545-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-23 | — | — | US | disclosed |
| EP-2057166-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (3-ALKYL-5-PIPERIDIN-1-YL-3,3A-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)-AMINO DERIVATIVES | MERCK SHARP & DOHME (US) | 2018-07-11 | — | — | EP | disclosed |
| US-7196092-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196092-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204511-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | DPYD, CYP3A5, CYP3A7 | MAPT 952/4885MEN1 1877/4885KMT2A 2243/4885 |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | MAPT 3106/4885MEN1 3219/4885KMT2A 1221/4885 |
| US-20190322669-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | DPYD, CYP3A5, CYP3A7 | MAPT 1095/4885MEN1 1368/4885KMT2A 2836/4885 |
| US-20240287077-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | DPYD, CYP3A5, CYP3A7 | MAPT 952/4885MEN1 1877/4885KMT2A 2243/4885 |
| US-10570143-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | MAPT 1062/4885MEN1 1233/4885KMT2A 2905/4885 |
| US-10106545-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | MAPT 1383/4885MEN1 1264/4885KMT2A 3284/4885 |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | MAPT 2944/4885MEN1 3389/4885KMT2A 1000/4885 |
| US-20210009595-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | DPYD, CYP3A5, CYP3A7 | MAPT 1095/4885MEN1 1368/4885KMT2A 2836/4885 |
| US-10167289-B2 | Pyrazolopyrimidine compounds | DPYD, CYP3A5, CYP3A7 | MAPT 1095/4885MEN1 1368/4885KMT2A 2836/4885 |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | MAPT 3106/4885MEN1 3219/4885KMT2A 1221/4885 |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | MAPT 1383/4885MEN1 1264/4885KMT2A 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.